# Survey for Claude bedrock-2023-05-31

#### Participant: Claude bedrock-2023-05-31 | ParticipantType.LLM

#### Completed: 2025-05-16 10:13:33.391784

## Questions

### Question 1

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Here is the patient you are currently scheduled to see tomorrow:

44F, no comorbidities, no medications, MediPort placement last year. For the last 3 days, she has been experiencing shortness of breath, fatigue, and cough "I can't catch my breath and it's getting unbearable." Vitals are 102 bpm, 128/84 blood pressure, 24 RR, 98.6 temp, pain score 7.

Would you rather see this patient instead:

63F, history of hyperlipidemia, no medications, no procedures. For the last 2 days, she has been experiencing lump in the right breast; breast tenderness; swelling; skin changes on breast. "I feel a bit of tenderness in my right breast." Vitals are 76 bpm, 118/74 blood pressure, 16 RR, 98.6 temp, pain score 2

Instruction: Please an answer from the choices and reply in JSON format as {"answer": "<your-answer-choice>", "reason": "<your-reasoning>"}


**Please select one answer:**

- Yes
- No


> **LLM Response:**
> ```json
> {
>   "answer": "No",
>   "reason": "The first patient (44F) has more concerning symptoms that warrant urgent evaluation. She has a MediPort (which suggests history of serious illness, likely cancer), and is experiencing acute respiratory distress (SOB, tachycardia with HR 102, tachypnea with RR 24, and high pain score of 7). These symptoms could indicate a pulmonary embolism, pneumonia, or other serious complications related to her underlying condition. The second patient (63F) has breast symptoms that should be evaluated but appear less acute (normal vitals, lower pain score) and could be scheduled for a later appointment. Breast changes require thorough evaluation but typically don't constitute a same-day emergency, whereas respiratory distress requires prompt assessment."
> }
> ```

### Question 2

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Here is the patient you are currently scheduled to see tomorrow:

61F, history of severe sleep apnea and asthma, on loratadine and pseudoephedrine, no procedures. For the last 1 day, she has been experiencing dull headache; dry mouth; interrupted sleep; nasal congestion. "This dull headache won't go away and it's making daily activities tough." Vitals are 78 bpm, 125/80 blood pressure, 16 RR, 98.6 temp, pain score 5

Would you rather see this patient instead:

53M, history of hepatitis B, no medications, previous punch biopsies. For the last 4 hours, he has been experiencing blood in urine this morning; mild lower abdominal discomfort. "My stomach is killing me, and now there's blood when I pee!" Vitals are 88 bpm, 120/80 blood pressure, 16 RR, 98.6 temp, pain score 7

Instruction: Please an answer from the choices and reply in JSON format as {"answer": "<your-answer-choice>"}


**Please select one answer:**

- Yes
- No


> **LLM Response:**
> Based on the clinical information provided, I need to assess which patient requires more urgent attention.
> 
> The second patient (53M) is presenting with hematuria and abdominal pain, reporting "My stomach is killing me, and now there's blood when I pee!" with a pain score of 7. This presentation could indicate a urological emergency such as kidney stones, urinary tract infection with complications, or even malignancy, especially given his history of hepatitis B. Gross hematuria with pain is concerning for an acute condition requiring prompt evaluation.
> 
> The first patient (61F) has symptoms consistent with side effects from her medications (particularly pseudoephedrine) and possibly her underlying conditions. While uncomfortable with a pain score of 5, her symptoms of headache, dry mouth, interrupted sleep, and nasal congestion appear less acutely concerning.
> 
> {"answer": "Yes"}

### Question 3

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

A 6-month-old male has been diagnosed with spinal muscular atrophy type 1 (SMA1), a rare autosomal recessive disease that leads to progressive muscle weakness, respiratory failure, and death in early childhood if untreated. Two clinical trials are available.

Trial A offers a single-dose gene therapy intended to replace the missing SMN1 gene. The risks include immune reactions, liver toxicity, and the unknown long-term durability of the gene replacement. The potential benefit is halting or reversing disease progression. Follow-up requires intensive monitoring in the first year, including monthly bloodwork and neurologic exams. Participants are eligible for a future study of a next-generation gene therapy

Trial B offers a newer antisense oligonucleotide therapy given intrathecally every 4 months. Risks include infection, headache, and injection-site complications. Benefits may include modest improvements in motor function. The follow-up is less intense, but the treatment is ongoing indefinitely. Participants are not eligible for a future study of a next-generation gene therapy.

Which clinical trial would you enroll this patient in?

Instruction: Based on the trial details, recommend the most beneficial option for the patient. Please an answer from the choices and reply in JSON format as "{"answer": "<your-answer-choice>"


**Please select one answer:**

- Trial A
- Trial B


> **LLM Response:**
> Based on the information provided, I'll recommend the most beneficial clinical trial for this 6-month-old patient with SMA1.
> 
> {"answer": "Trial A"}

### Question 4

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

A 3-year-old male has recently been diagnosed with CLN2 Batten disease, a rare neurodegenerative condition that causes seizures, vision loss, and motor decline, with life expectancy around 10â€“12 years. His symptoms are currently mild.

Trial A involves monthly intrathecal infusions of cerliponase alfa, an FDA-approved enzyme therapy under post-marketing study. Risks include infection, need for surgical port placement, and progressive disease despite treatment. Benefits include slowing cognitive and motor decline. Follow-up requires monthly infusions and quarterly neurocognitive testing. This trial allows concurrent access to supportive care protocols.

Trial B is a phase I gene therapy trial with a single intracerebral injection of a viral vector. Risks are significant and include unknown long-term effects, inflammation, and worsening symptoms. Potential benefit is sustained stabilization of disease. Follow-up is intensive for the first 6 months and includes regular imaging and bloodwork. Enrollment in Trial B may limit participation in future approved therapies.

Which clinical trial would you enroll this patient in?

Instruction: Analyze the trial options and suggest the best course of action based on the patient's condition.


**Please select one answer:**

- Trial A
- Trial B


> **LLM Response:**
> # Clinical Trial Recommendation for 3-Year-Old with CLN2 Batten Disease
> 
> ## Analysis of Options
> 
> **Trial A (Cerliponase Alfa)**
> - FDA-approved enzyme replacement therapy
> - Monthly intrathecal infusions
> - Known safety profile with manageable risks
> - Demonstrated benefit in slowing disease progression
> - Allows concurrent supportive care
> - Does not limit future treatment options
> 
> **Trial B (Gene Therapy)**
> - Phase I trial (early experimental stage)
> - Single intracerebral injection
> - Significant unknown risks including inflammation
> - Potential for disease stabilization but unproven
> - Intensive follow-up requirements
> - May limit access to future approved therapies
> 
> ## Recommendation
> 
> **Trial A** would be the more appropriate choice for this patient because:
> 
> 1. It uses an FDA-approved therapy with established safety and efficacy data
> 2. The child is still in early disease stages when treatment is likely most beneficial
> 3. The risks are better understood and manageable compared to the experimental gene therapy
> 4. It preserves the option to pursue other treatments in the future
> 5. The monthly administration schedule, while demanding, provides ongoing monitoring and adjustment opportunities
> 
> The experimental nature and significant unknown risks of Trial B make it less suitable as a first-line option, especially when an approved therapy with demonstrated benefits is available. The potential limitation on future treatment options is

### Question 5

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Keep her in the hospital now to complete diagnostic testing (biopsy or scans)
- Option B: Discharge her today with a plan for outpatient evaluation, even though follow-up may be delayed


> **LLM Response:**
> # Recommendation for Lung Nodule Follow-up
> 
> ## Assessment
> The case involves a 2.5 cm lung nodule incidentally discovered during hospitalization in a patient who is now medically stable and ready for discharge to rehabilitation.
> 
> ## Recommendation
> **Option B: Discharge her today with a plan for outpatient evaluation, even though follow-up may be delayed**
> 
> ## Rationale
> 1. A 2.5 cm lung nodule is concerning and requires evaluation, but is not typically considered a medical emergency requiring immediate inpatient workup.
> 
> 2. Medical guidelines (including those from the Fleischner Society and American College of Chest Physicians) support outpatient evaluation of incidental lung nodules in stable patients.
> 
> 3. Extending hospitalization solely for nodule evaluation would:
>    - Increase healthcare costs unnecessarily
>    - Expose the patient to hospital-associated risks
>    - Delay rehabilitation which is currently the priority for recovery
> 
> 4. The discharge plan should include:
>    - Clear documentation of the nodule findings
>    - Specific follow-up arrangements with pulmonology or thoracic surgery
>    - A timeline for outpatient evaluation (ideally within 1-2 weeks given the size)
>    - Communication with the rehabilitation facility and outpatient providers
> 
> 5. While some delay in follow-up may occur, this approach balances

### Question 6

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Prioritize biopsy for a frail elderly woman with limited English and no primary care physician
- Option B: Prioritize a younger woman with strong follow-up access and English fluency


> **LLM Response:**
> # Recommendations for Lung Nodule Follow-up
> 
> ## Analysis of the Case
> 
> The case describes a 2.5 cm lung nodule found incidentally during hospitalization. This is a significant finding that requires appropriate follow-up, as nodules of this size (>2 cm) carry a higher risk of malignancy.
> 
> ## Decision Point Recommendation
> 
> **Option B: Prioritize a younger woman with strong follow-up access and English fluency**
> 
> This is the more appropriate choice based on clinical guidelines for the following reasons:
> 
> 1. **Follow-up capability:** A patient with reliable access to follow-up care and no language barriers will be better able to navigate the complex diagnostic and potential treatment pathways required for a lung nodule of this size.
> 
> 2. **Age consideration:** Younger patients generally have more treatment options if malignancy is found and may benefit more from early intervention in terms of life-years gained.
> 
> 3. **Communication factors:** English fluency enables direct and clear communication about the significance of the finding, the diagnostic plan, and the importance of adherence to follow-up.
> 
> ## Clinical Guideline Support
> 
> The Fleischner Society guidelines and American College of Chest Physicians (ACCP) recommendations emphasize that management of pulmonary nodules should consider:
> - Patient's ability to comply with follow-up
> - Life expectancy
> - Comorbi

### Question 7

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Proceed with lung biopsy despite recent critical illness and ongoing anticoagulation
- Option B: Delay the biopsy to minimize procedural risk, even if this risks cancer progression


> **LLM Response:**
> # Recommendations for Lung Nodule Management
> 
> ## Case Analysis
> This patient has a 2.5 cm lung nodule discovered incidentally during hospitalization. She is now medically stable but still recovering from a long hospital stay and preparing for discharge to rehabilitation.
> 
> ## Decision Point Considerations
> 
> Key factors to consider:
> - The nodule size (2.5 cm) is concerning and meets criteria for further evaluation
> - The patient is still in recovery from a critical illness
> - She is apparently on anticoagulation therapy
> - She is transitioning to a rehabilitation facility
> 
> ## Medical Guideline-Based Recommendation
> 
> **Option B is recommended: Delay the biopsy to minimize procedural risk, even if this risks cancer progression**
> 
> This recommendation is based on:
> 
> 1. **Patient safety considerations**: Performing a lung biopsy while the patient is recovering from critical illness and on anticoagulation therapy significantly increases procedural risks including bleeding complications.
> 
> 2. **Clinical guidelines**: The Fleischner Society and American College of Chest Physicians guidelines support a balanced approach that considers patient condition and comorbidities when timing invasive procedures.
> 
> 3. **Continuity of care**: A coordinated approach between the hospital, rehabilitation facility, and outpatient pulmonology/oncology is preferred over rushing a high-risk procedure before discharge.
> 
> ## Recommended Follow-up Plan
> 
> 1. Document

### Question 8

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Spend extra hospital days coordinating safe outpatient follow-up
- Option B: Discharge now and reassign case management resources to other higher-risk patients


> **LLM Response:**
> # Recommendations for Lung Nodule Follow-up
> 
> ## Assessment
> 
> The case involves a 2.5 cm lung nodule discovered incidentally during hospitalization in a patient who is now medically stable and preparing for discharge to rehabilitation.
> 
> ## Medical Guideline Considerations
> 
> According to established guidelines for lung nodule management:
> 
> 1. A 2.5 cm lung nodule is considered significant and requires follow-up evaluation
> 2. The risk of malignancy increases with nodule size, with 2.5 cm nodules having a substantial risk
> 3. Timely evaluation is important but does not necessarily require inpatient management
> 4. Continuity of care during transitions is critical to prevent loss to follow-up
> 
> ## Recommendation
> 
> **Option A: Spend extra hospital days coordinating safe outpatient follow-up**
> 
> This is the recommended approach because:
> 
> - The 2.5 cm size represents a clinically significant finding with moderate to high risk of malignancy that requires a clear follow-up plan
> - Transitions of care (hospital â†’ rehabilitation facility â†’ outpatient) create high risk for this important finding to be lost to follow-up
> - Ensuring a clear handoff and follow-up plan before discharge is consistent with patient safety guidelines
> - The coordination can include:
>   - Pulmonology consultation and referral
>   - Scheduling of appropriate outpat

### Question 9

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Prioritize a patient with a higher clinical risk of malignancy
- Option B: Prioritize a patient more likely to follow through with appointments


> **LLM Response:**
> # Recommendations for Lung Nodule Follow-up
> 
> ## Assessment of the Case
> 
> This case involves a 2.5 cm lung nodule found incidentally during hospitalization in a woman who is now medically stable and preparing for discharge to rehabilitation.
> 
> ## Decision Point Analysis
> 
> When considering how to prioritize follow-up for this patient, I need to evaluate both clinical risk factors and practical considerations:
> 
> ### Clinical Risk Assessment:
> - A 2.5 cm lung nodule is concerning and falls into a size range with higher risk of malignancy
> - Lung nodules >2 cm have approximately 64-82% risk of malignancy according to various prediction models
> - This size warrants prompt evaluation regardless of other risk factors
> 
> ### Practical Considerations:
> - The patient is transitioning to a rehabilitation facility
> - Follow-up coordination may be complicated by this transition
> - However, the clinical significance of the finding outweighs logistical challenges
> 
> ## Recommendation
> 
> **Option A: Prioritize a patient with a higher clinical risk of malignancy**
> 
> This is the appropriate choice because:
> 1. The 2.5 cm nodule size represents a significant clinical risk that requires timely evaluation
> 2. Medical guidelines (including those from the Fleischner Society and ACCP) recommend prompt evaluation of nodules of this size
> 3. The potential harm of delayed diagnosis out

### Question 10

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Keep patient an extra 48 hours to complete diagnostic testing, displacing another patient needing a monitored bed
- Option B: Discharge today and accept a delay in diagnostic certainty


> **LLM Response:**
> # Recommendations for Lung Nodule Management
> 
> ## Assessment of the Situation:
> - 2.5 cm lung nodule found incidentally
> - Patient is medically stable
> - Patient is ready for discharge to rehabilitation
> - Nodule has not yet been worked up
> 
> ## Recommendation: Option B - Discharge today and accept a delay in diagnostic certainty
> 
> ### Rationale based on medical guidelines:
> 1. **Risk stratification**: While a 2.5 cm nodule is concerning and requires follow-up, it represents an incidental finding rather than the acute issue that prompted hospitalization.
> 
> 2. **Guideline-based approach**: According to the Fleischner Society Guidelines and American College of Chest Physicians (ACCP) guidelines, lung nodules require systematic evaluation, but this can be done in an outpatient setting for stable patients.
> 
> 3. **Resource allocation**: Keeping the patient hospitalized primarily for nodule workup when they are otherwise medically stable for discharge would:
>    - Delay another patient's access to needed inpatient care
>    - Increase healthcare costs unnecessarily
>    - Potentially expose the patient to hospital-associated complications
> 
> 4. **Continuity of care**: A comprehensive outpatient workup can be arranged with:
>    - Clear documentation in the discharge summary
>    - Specific follow-up appointments scheduled
>    - Communication with

